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INTRODUCTION
In the last decade increasing efforts have been made to clas-
sify mental disorders on the basis of objective makers1-4 claim-
ing that markers can clarify the aetiology of psychiatric diseas-
es, confirm a diagnosis, identify “at risk” individuals, determine 
the severity of mental illness, predict the course of the disor-
der.1,2,5 Some authors also suggested that the use of markers 
might lead to personalized psychiatric treatments approach 
and inform about the type, timing, and course of interven-
tions to be used as well as monitoring the clinical response 
to them.1,2,5 Of course, markers must have at least a moder-
ate level of sensitivity, specificity, and predictive value2 to be 
useful. In this vein, markers were classified as: 1) susceptibil-
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ity/risk marker, i.e., the marker indicates the potential for de-
veloping a disease in an individual who, from a clinical stand-
point, does not have that disease or medical condition clinically 
relevant, yet; 2) diagnostic marker, i.e. a marker used to iden-
tify individuals with the disease or to define a subset of the 
disease; 3) prognostic markers, i.e., markers used to identify 
the likelihood of a clinical event, disease recurrence or pro-
gression in patients who have the disease or medical condi-
tion of interest; 4) predictive markers, i.e., markers used to 
identify individuals who are more likely than those without 
the marker to experience a favourable or unfavourable effect 
from specific intervention or exposure; it provides a forecast 
of the potential for a patient to respond to one or more spe-
cific treatments.6-8
METHODS
A computerized search was carried out in PubMed and Sci-
ence Direct. Search terms were: “marker/biomarker/clinical 
marker/neurobiology/staging” combined using Boolean AND 
operator with “panic.” In addition, the reference lists from ex-
isting reviews and from the articles retrieved were inspected. 
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Only English language papers published in peer-reviewed jour-
nals were included. 
RESULTS
Biological markers in panic disorder
A biomarker is defined as a characteristic that is objectively 
measured and evaluated as an indicator of normal biologic 
processes, pathologic processes, or biological responses to a 
therapeutic interventions.3,4 We will here illustrate the bio-
logical markers proposed for panic disorder (PD) on the ba-
sis of the literature.
Structural or activity changes in brain regions 
According to Bandelow et al.,9,10 structural changes in the 
volume of amygdala, hippocampus, parahippocampal gyri, 
and brainstem nuclei are candidate biomarkers of panic dis-
order. Volume reduction or increase in these areas as well as 
increased activation of amygdala and hippocampus in re-
sponse to fearful stimuli have been reported in PD patients 
but not in controls (p value ranging from 0.002–0.005).9,10 
Some evidences suggested a greater activation in PD patients 
than in controls at the level of the insular cortices, of the left 
inferior frontal gyrus, of the dorsomedial prefrontal cortex, 
and of the left caudatum.9,10 A negative correlation between 
left amygdala volume and anxiety was found in PD patients 
(r=-0.54; p=0.02).11
The cerebral blood flow in the left occipital cortex and the 
serotonin (5-TH) and noradrenaline (NE) system activation 
were also proposed as putative biomarkers.9,10 Compared to 
controls, patients with PD showed a higher cerebral blood 
flow (mean±SD 1.35±0.01 vs. 1.24±0.02, p<0.05)12 and low-
er 5-TH plasma levels9,10 in addition a significant association 
between a hyperactivation of the NE system, anxiety, and so-
matic symptoms was found in PD patients but not in patients 
with other psychiatric disorders (e.g., generalized anxiety dis-
order, obsessive compulsive disorder, depression and schizo-
phrenia).9,10,13 These findings were consistent with Gorman’s 
neuroanatomical hypothesis of PD.14
Respiratory patterns 
Several theories sharing the hypothesis of a causal rela-
tionship between aberrant respiratory regulation and panic 
have been developed.15-19 Both respiratory symptoms during 
panic attacks and behavioral and respiratory hypersensitivi-
ty to hypercapnic gas mixture inhalation have been found in 
PD patients.15-19 In these subjects, hyperventilation may be 
chronic.16 In addition, hyperventilation (e.g., higher baseline 
mean minute ventilation, lower end-tidal partial pressure of 
CO2, and lower venous pCO2), higher variability of mean min-
ute ventilation, higher respiration rate, higher tidal volume, 
higher rate of sighs and apnoea in respiratory patterns were 
found in PD patients but not in healthy controls (effect size 
Hedges’ g ranging from -0.73 to 0.39, p<0.01). Grassi et al.17 
verified whether these respiratory abnormalities are specific 
to PD or are also present in anxiety disorders other than PD. 
Lower baseline mean et-pCO2, indicating a condition of hy-
perventilation (effect size Hedges’ g ranging from -0.28 to 
-0.56, p<0.01) and higher respiration rate (effect size Hedges’ 
g ranging from 0.25 to 0.47, p<0.01) were found in PD pa-
tients but not in those with social phobia or generalized anxi-
ety disorder.17 Thus, the aberrant respiratory pattern (i.e., hyper-
ventilation and higher respiration rate) seems to be a biomarker 
specific for PD. 
Hearth rate variability, blood cells, peripheral blood 
stem cells 
The hearth rate variability (HRV) (i.e., the extent to which 
the interval between beats varies with time) was also assumed 
as a candidate biomarker for PD.9,20 HRV is a core feature of 
cardiovascular diseases21 which was found to be positively 
correlated with panic attacks across clinical and non-clinical 
samples.9,22,23 The HRV was considered a possible core feature 
of PD9,10,22,23 on the basis of studies reporting an increased 
risk of cardiovascular diseases in PD patients than in subjects 
without psychiatric disorders24 and a prevalence of panic dis-
order ranging from 4% to 12.5% in cardiac outpatients. HRV 
is measured using the time domain (i.e., differences between 
adjacent beat intervals) and frequency domain (i.e., measures 
based on power spectral analysis, which allows detection of 
lower and high frequency oscillation).9,10,20 A meta-analysis20 
reported that time and frequency domains were significantly 
lower in patients with PD than in healthy controls, beyond 
potential confounding effects of medication use and medical 
and psychiatric co-morbidity (effect size Hedges’ g ranging 
from -0.69 to -0.29, p<0.05). Chalmers et al.20 reported simi-
lar findings comparing patients with anxiety disorders other 
than PD (i.e., post traumatic stress disorder, generalized anxi-
ety disorder, social anxiety) with healthy controls; they showed 
that HRV is an aspecific marker across anxiety disorders.9,10,20 
Recent findings25 observed increased platelet distribution 
width (PDW), red cell distribution width (RDW), and mean 
platelet volume (MPV) in PD patients if compared to healthy 
controls. These results emphasized the role of blood cells 
and peripheral blood stem cells as possible biomarkers of 
PD25-27 in accordance with the theory of the inflammatory or-
igin of PD.26
Hypothalamic–pituitary–adrenal axis dysregulation 
It has been assumed that panic attacks might be a result of 
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a disturbance in stress response regulation by the strong acti-
vation of the hypothalamic–pituitary–adrenal (HPA) axis.28 
The HPA axis is the major endocrine system which regulates 
the physiological response to stress and as a result drive how 
an organism might adapt its own behavior or environment in 
order to copy with that stress.29-31 When the stress is persistent, 
the negative feedback system, which dampens the HPA axis 
activation, is impaired inducing chronic cortisol release29,32 
which may provoke flatter circadian variation and heightened 
daily cortisol secretion.29-32
Studies addressing the role of HPA axis activation in panic 
disorder used cortisol secretion as index of the HPA func-
tioning during panic attacks or compared PD patients with 
controls. These studies provided inconsistent results. Some 
reported a higher cortisol secretion during panic attacks com-
pared to the values obtained in the same individuals at com-
parable times on panic-free days.28,33 Other studies reported 
unchanged or only marginal HPA axis activation during spon-
taneous attacks.28 In addition, while some evidences report-
ed higher cortisol secretion in PD patients when compared 
to controls, other studies showed comparable levels of corti-
sol between PD patients and healthy controls.9,10,28,32,34 As 
pointed out by Bandelow et al.,35 it is not clear whether the 
dysfunctions of the HPA axis are a potential cause of PD or a 
consequence of permanent stress induced by recurrent panic 
attacks. 
These heterogeneous findings might be explained by sev-
eral elements; first, at the beginning of the panic attack the 
HPA axis activation might be due to an arousal in reaction to 
novelty cues and/or to anxiety anticipatory about further at-
tack and/or the avoidance of places where having an attack is 
embarrassing develop;32,34,36,37 second, after the acute phase 
of a panic attack, the HPA axis might normalize due to a suc-
cessful habituation to the repeated experiences of panic.32,34,38 
However, the role of cortisol secretion as biomarker of PD is 
not fully confirmed.
Classification of putative biomarkers of PD 
As previously reported, markers might be categorized as 
susceptibility/risk markers; diagnostic, prognostic, and pre-
dictive markers.6-8 Given that the biomarkers illustrated were 
found in PD patients and not in controls,9,10,16,17,20,25 they might 
be considered susceptibility and/or diagnostic biomarkers, 
however longitudinal studies are warranted to confirm this. 
Also the HPA axis dysregulation and the heart rate variability 
might be considered prognostic biomarkers given that high-
er cortisol secretion was found to predict poorer long-term 
outcome in PD patients at 2–4 year follow-up (p<0.003)39,40 
and lower HRV in PD patients might increase vulnerability 
to cardiovascular diseases.41 Predictive biomarkers of PD are 
still unclear due to the inconsistency of results. Grambal et 
al.42 suggested that increased pre-treatment activation of the 
dorsolateral prefrontal cortex, right parietal cortex, left fron-
tal eye field, orbito-frontal cortex, and left amygdala predict 
poor outcome in cognitive behaviour therapy; Bandelow et 
al.9 and Fisher et al.43 reported that neither brain regions struc-
tural changes nor basal cortisol concentrations predict re-
sponses to psychological treatments. In Table 1 we reported a 
proposal for classifying PD biomarkers.
The biomarker crisis
A body of research on biomarkers considered single brain 
region/circuit or a specific neurotransmitter without ravel-
ling one-to-one relationships with a specific disease.4 Given 
that mental disorders are multidimensional in their descrip-
tion, multifactorial in their origins, and involve non-linear in-
teractions in their development,44 it is unlikely that a single 
biomarker might explain the multifaceted nature of a specif-
ic psychiatry disease.2,45 Multimodal approach where the di-
agnosis and/or the course of diseases are explained by a com-
Table 1. Putative makers of panic disorder classified as: susceptibility/risk marker; diagnostic marker, prognostic marker, predictive marker6-8
Susceptibility/
risk marker
Diagnostic 
marker
Prognostic 
marker
Predictive 
marker
Biomarkers
Structural changes in the amygdala, hippocampus ?
Cerebral blood level in the left occipital cortex ?
Serotonin 5-TH and noradrenergic systems activation ?
Aberrant respiratory regulation ? ?
Hearth rate variability ?
Blood cells and peripheral blood stem cells ?
Dysregulation hypothalamic–pituitary–adrenal axis/Cortisol secretion ? ?
Clinical marker
Staging ? ? ? ?
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bination of different biomarkers could be more reliable.2,4,45 
Moreover, it is likely that different biomarkers are associated 
with a cluster of symptoms rather than to a specific diagno-
sis.2,4,45 A further hurdle is that some biomarkers, as for ex-
ample structural changes in the amygdala and/or hippocam-
pus, although they showed acceptable reliability,9,10 can be 
used in clinical practice rarely for practical and economic rea-
sons.45 To facilitate the use of biomarkers on a broad-based 
scale, we would need simple and cost-effective biomarkers2,45 
such as for instance urine or saliva cortisol, heart rate variabil-
ity, blood cells, peripheral blood stem cells, or respiratory pat-
tern.9,10,16,17,20,25 However, although the biomarkers mentioned 
for PD showed high sensibility in distinguishing PD from 
the healthy condition, they did not show enough specificity in 
distinguishing PD from other psychiatric disorders.9,10 Basi-
cally, the identification of biomarkers is based on observations 
that the specific biomarker is detected in PD patients and not 
in healthy controls or in patients with other psychiatric dis-
orders.9,10,45 This might lead to interpretative bias given that, 
due to an overlap in pathophysiological findings among psy-
chiatric disorders, biomarkers might be shared by different 
psychiatry disorders. Most of the candidate biomarkers de-
scribed above (e.g., structural brain morphology, lower 5-HT 
plasma, norepinephrine, hypo/hyper secretion of cortisol, in-
stability of the cortical arousal system, HRV, PWD and RDW) 
differentiate PD patients form healthy controls but not PD pa-
tients from patients having other psychiatric disorders, such as 
anxiety disorders, schizophrenia, mood disorders.9,10,46-58
The lack of availability of biomarkers with high specificity 
has been widely discussed.45,59,60 As reported by Kapur et al.,60 
psychiatry seems to be in a Catch-22 given that the contem-
porary diagnostic system was not designed to facilitate bio-
logical differentiation. In addition, current diagnostic defini-
tions of psychiatric disorders based on symptoms encompass 
very heterogeneous populations and are thus likely to yield 
spurious results when exploring biological correlates of men-
tal disturbances.59
To be also noted that biomarkers are influenced by envi-
ronmental and lifestyle factors such as stress, physical activity, 
comorbidity, psychotropic medications.45 Psychotropic drug 
treatments, particularly after long-term use, might cause or 
precipitate adverse effects on the course, characteristics, and 
responsiveness of an illness that do not necessarily subside 
with discontinuation of the drug or of modifying responsive-
ness to subsequent treatments.61,62 Such vulnerabilities are sub-
sumed under the rubric of iatrogenic comorbidity.61,62
Psychometric and clinimetric approach
The psychometric approach aims to develop instruments 
that measure a single construct using multi-items,63 given that, 
its customary goal is to achieve a unidimensional construct in 
which the relatively homogeneous components all measure 
essentially the same phenomenon.63,64 Methodological diffi-
culties in applying psychometric principles to diagnostic test-
ing and to detect changes related to the course of illness and/
or to difference between pre- and post-treatment have been 
outlined.64 Wright and Feinstein65 provide an explanation for 
the disappointing performance that multi-item scales may 
present. In psychometrics, the homogeneity of components 
is considered as the most important requirement for a rating 
scale; however, the same properties that give a scale a high 
score for homogeneity, as the redundant nature of the items 
of a scale, may obscure its ability to detect change decreasing 
its sensitivity.65 A high correlation between scales is also re-
garded as evidence that the two scales measure the same fac-
tor, but a high correlation does not indicate similar sensitivity: 
a common content of two scales may ensure a high positive 
correlation between them, but the items they do not share may 
be important in determining their sensitivity.64,66 On the basis 
of the psychometric approach all items of a scale have same 
weight.66 Although multi-item scales might be valid and reli-
able, it might show lack sensitivity.66,67
Fava et al.66 suggested that psychometrics has now become 
an obstacle to the progress of clinical research in psychiatry 
and clinical psychology and that the more clinically oriented 
clinimetrics could offer a valid alternative. Clinimetrics’ is 
the term introduced by Feinstein in the early 1980s68 to indi-
cate a domain concerned with the measurement of clinical 
issues that do not find room in customary clinical taxonomy. 
Such issues include types, severity and sequence of symp-
toms; rate of progression in illness (staging); severity of co-
morbidity; problems of functional capacity; reasons for med-
ical decisions (e.g. treatment choices), and many other aspects 
of daily life, such as well-being and distress.68 Differently from 
the psychometric approach, in clinimetrics homogeneity of 
components is not needed and single items may be weighed 
in different ways: what matters is the capacity of an index to 
discriminate between different groups of subjects and to re-
flect changes in experimental settings.64,66 In addition, the 
clinimetric approach is directed at the development of instru-
ments to measure multiple constructs with a single index that 
might be divided into ailment-oriented indexes (refer to spe-
cific diseases, states and clinical manifestations) and general 
indexes (refer to general health and functional states that are 
not distinctive for a particular disease or condition).64,66 The 
clinimetric analysis proposed convergent, discriminant, and 
incremental validity as important features that determine the 
sensibility of a clinical measurement.69-71 
The current diagnostic systems, the Diagnostic and Statis-
tical Manual of Mental Disorders (DSM)72-76 and the Interna-
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tional Classification of Diseases (ICD),77-80 are mostly influ-
enced by psychometric models according to which the severity 
of the disorder is determined by the number of symptoms 
rather than to their intensity or quality.66,81,82 Thus, all symp-
toms have an equivalent value and load in determining the 
severity of a psychiatric disorder, unlike in clinical medicine 
where major and minor symptoms are often differentiated 
(e.g., the Jones criteria for rheumatic fever).68 This might 
bias the diagnostic process given that psychological symp-
toms that do not reach the diagnostic threshold might be not 
considered83 although they might affect the quality of life of 
the patient and lead to pathophysiological and therapeutic 
implications.67 In addition, different patients could meet the 
diagnostic criteria for the same disorder but presenting dif-
ferent scores on a rating scale which reflect different symp-
tom severities, perceptions, and illness attitudes, that in turn 
might affect the clinical course of the disorder.67 Differently 
form the psychometric models, clinimetrics assumed that 
different symptoms have different weigh.67 Moreover, clini-
metrics approach focuses on symptoms sequence, rate of pro-
gression of illness, and comorbidity, and on problems of 
functional life, such as well-being.64,66,67
Clinical markers in panic disorder 
From cross-sectional diagnostic systems to the staging 
model
Even thought the current diagnostic systems72-80 showed 
acceptable reliability, their clinical utility remains elusive.84-86 
In a large epidemiological survey run on a sample of 1,764 us-
ers of ICD or DSM, it was evident that 1,123 subjects (64%) 
rated those diagnostic systems as with low utility in selecting 
a treatment and assessing probable prognosis.84 This might 
be partially explained by the several reasons. First, the taxon-
omy in psychiatry derived from the traditional method of 
clinical medicine which provides operating specifications for 
making a clinical decision about the existence of a specific dis-
ease.87 As a consequence, the diagnostic reasoning process ends 
with the identification of a disorder88 while, in reality, the clini-
cal judgment should go through a series of ‘transfer stations’ 
where potential connections between presenting symptoms 
and pathophysiological processes are drawn and are amena-
ble to longitudinal verification and modification as long as 
therapeutic goals are achieved.81,89-91 Second, the diagnostic 
systems are mostly influenced by psychometric models;81-83 
as a result: 1) patterns of symptoms, severity of illness, ef-
fects of comorbid conditions, timing of phenomena, rate of 
progression of illness (staging), responses to previous treat-
ments, and other clinical distinctions that might demarcate 
major prognostic and therapeutic differences among patients 
who otherwise might be deceptively similar since they share 
the same psychiatric diagnosis are poorly taken into account; 
2) the target of therapy tends to become syndromes resulting 
from a certain number of symptoms, that could be of mild in-
tensity and of doubtful impact on quality of life, instead of 
symptoms that might be incapacitating for the patient.81 With-
in a sample of patients with major depressive episode, the 
number of symptoms (either including all depressive symp-
toms or selecting only those relevant to a DSM diagnosis) 
does not correlate with the illness severity which was instead 
strongly correlated with certain symptoms than other ones.92 
Exclusive reliance on diagnostic criteria impoverishes the 
clinical process and does not reflect the complex thinking that 
underlies decisions in psychiatric practice.89 The mental dis-
orders are not static, sharply defined illnesses with separate 
aetiologies and courses, but rather syndromes that overlap 
and develop in stages.86,93
Moving from a cross-sectional nosography to the longitu-
dinal view of the development of psychiatric disorders, stag-
ing was proposed as a strategy to improve the diagnostic and 
treatment process in psychiatry and clinical psychology.67,68,86
The use of staging in psychiatry 
Staging86,94 allows to define the extent of progression of a 
disorder at a particular point in time and where a person is 
currently located along the continuum of the course of the ill-
ness; define prodromes (e.g. early symptoms and signs that 
differ from the acute clinical phase) and residual symptoms 
(e.g. persistent symptoms and signs despite apparent remis-
sion or recovery); characterize a psychiatric disorder develop-
ment according to different stages.94 In 2013, Cosci and Fava86 
systematically reviewed the literature to synthesize the differ-
ent models of staging available in psychiatry and clinical psy-
chology across different diagnostic categories such as schizo-
phrenia, unipolar depression, bipolar disorder, panic disorder, 
substance use disorders, anorexia and bulimia nervosa. 
As stage 1 they found the prodromal phase, defined as the 
time interval between the onset of prodromal symptoms 
and the onset of the characteristic manifestations of the fully 
developed illness.86 After the acute phase (stage 2), it might 
be difficult to assess whether partial or full remission has oc-
curred; attenuated symptoms, the so called residual symptoms, 
might be observed at stage 3; they are due to partial persis-
tence of the disorder or an aggravation of a pre-existing ab-
normal personality trait.86 Stage 4 represents chronicity of the 
psychiatric disorder.86 
Staging as clinical marker of panic disorder
In 1993, Fava and Kellner94 described a staging model for 
PD with agoraphobia based on the fact that, in a substantial 
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proportion of patients, agoraphobia, hypochondriacal fears 
and beliefs, and generalized anxiety precede the first panic 
attack. However, given that for some patients, the first panic 
attack can occur without conspicuous prodromal symptoms, 
while anticipatory anxiety, phobic avoidance, and hypochon-
driasis may develop subsequently,95 Sheehan and Sheehan96 
proposed different staging process: stage 1 characterized by 
panic attacks with limited symptoms (subpanic); stage 2 is 
panic; stage 3 is hypochondriasis; stage 4 is single phobia; 
stage 5 is social phobia; stage 6 is agoraphobia, and stage 7 is 
depression. 
In 2008, Fava et al.97 proposed an updated version of the 
staging model of PD94 which was described as follows: stage 
1 defined by pre-agoraphobia with predisposing factors, 
such as health anxiety and anxiety sensitivity, genetic vulner-
ability, premorbid personality, hypochondriacal fears and 
beliefs and impaired psychological well-being; the relative 
weight of these factors may vary from patient to patient and 
lead to subtle avoidance patterns and to the stage 2, which is 
agoraphobia; stage 3 is characterized by the occurrence of panic 
attack; health anxiety may turn into hypochondriasis and/or 
disease phobia and/or thanatophobia; demoralization and/or 
major depression may occur; stage 4 in which the duration of 
PD with agoraphobia might predispose to the development 
of other psychiatric complications, as depression; agorapho-
bia may become more severe and hypochondriacal fears and 
beliefs may be accentuated.
As regard to the sub-clinical symptoms, the most com-
mon prodromal symptoms in PD were depressed mood, ill-
ness phobia, distress and avoidance of closed spaces, exces-
sive worries, negative affectivity, anxiety sensitivity and health 
anxiety or fear of disease; whereas the more prevalent residu-
al symptoms were generalized anxiety, somatic anxiety, health 
anxiety, low self-esteem, agoraphobia, hypochondriasis, re-
duced psychological and physical well-being, limited symptoms 
of panic attacks, anticipatory anxiety and depression.86,95,98,99 
Within the framework of the Diagnostic Criteria for Psycho-
somatic Research,100 the following subclinical symptoms were 
proposed given that all of them were found to be associated 
with PD and agoraphobia:99 disease phobia, somatization, ir-
ritable mood. Disease phobia might be part of the hypochon-
driacal syndrome, yet they may also occur independently; 
disease phobia differs from hypochondriasis for three charac-
teristics: fears concern a specific disease and are unlikely to be 
shifted to another disease or organ system; fears tend to man-
ifest themselves in attacks rather than in constant worries as 
in hypochondriasis; it often results in the avoidance of inter-
nal and external illness-related stimuli, while hypochondriasis 
involves reassurance-seeking or checking behaviors.100 Soma-
tization is conceptualized as a clustering of somatic symptoms 
involving different organ systems probably due to an enhanced 
general sensitivity to pain and discomfort.100 Irritable mood 
refers to the concept of irritability that might be part of psychi-
atric syndromes; it is always unpleasant for the individual and 
its overt manifestation lacks a cathartic effect.100
In 2013, the staging model was updated86 as follows (Table 
2): the prodromal phase (stage 1) was defined by the pres-
ence of subclinical symptoms of agoraphobia, social phobia, 
generalized anxiety disorder, hypochondriasis; these symp-
tom being stable during the acute phase (stage 2); panic attack 
start with subsequent worsening of anxiety and hypochondria-
cal symptoms and possible co-occurrence of demoralization 
and major depression (stage 3); PD might endure, in persis-
tent or attenuated form, with agoraphobia and/or social pho-
bia and/or generalized anxiety disorder and/or hypochon-
driasis, which in turn might predispose to the development of 
other psychiatric complications as depression (chronic phase, 
stage 4). 
The phenomenological clinical sequence of PD might be 
defined as follow: phobic avoidance and hypochondriasis 
leading to panic, which, in turn, leads to more phobic avoid-
ance and hypochondriasis. The rollback phenomenon might 
thus favour a decrease in avoidance by exposure, which im-
proves agoraphobia and panic, with eventual disappearance 
of panic, whereas agoraphobia persists although to a less de-
gree.95 Prodromal symptoms of PD might tend to become 
residual symptoms, which, in turn, may progress to prodro-
mal symptoms of relapse.95 Alternatively, the rollback phe-
nomenon might be characterized by anxiety elicited by bodi-
ly sensations, which influences catastrophic beliefs and such 
beliefs influence avoidant behaviour.95
According to the staging model, the acute phase of PD rep-
resents a “transfer station” from prodromal to residual symp-
toms.86 Within the staging framework seems unlikely that 
Table 2. Staging of panic disorder86
Stage 1 Prodromes: agoraphobia and/or social phobia and/or; generalized anxiety disorder and/or hypochondriasis
Stage 2 Acute manifestations of agoraphobia and/or social phobia and/or generalized anxiety disorder and/or hypochondriasis 
Stage 3 Panic attacks occur, panic disorder with aggravation of anxiety and/or hypochondriacal symptoms; demoralization and/or major 
depression 
Stage 4 Chronic (attenuated or persistent form): panic disorder and/or agoraphobia and/or social phobia and/or generalized anxiety 
disorder and/or hypochondriasis. Increased vulnerability to major depression 
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panic attack is a pathognomonic features of panic disorder, 
while it is plausible that it might be a trans-diagnostic risk fac-
tor for the development of agoraphobia and/or social phobia 
and/or generalized anxiety disorder, and/or hypochondria-
sis.86 The staging model of PD has been supported by a vast 
bulk of literature86 and can be a good clinical marker (Table 2) 
for PD: 
1) It is a “susceptibility/risk marker,” allowing to detect the 
presence of prodromal symptoms of PD (e.g., stage 1); 
2) It is a “diagnostic marker,” allowing to identify individ-
uals at each single stage of the disorder and the longitudinal 
evolution of PD across different stages;
3) It is a “prognostic marker,” Fava et al.101 underline the 
prognostic value of residual symptoms given that they are neg-
atively correlated with psychological well-being101 and that 
may represent the onset of prodromes of relapse. Thus, resid-
ual symptoms should be a target of therapy;95
4) It is a “predictive marker,” staging might improve the 
clinician’s ability to select a proper treatment to prevent the 
progression to further stages or promote regression to an ear-
lier stage.86 Stage-specific therapies have been shown to be ef-
fective for depression.102 Furthermore, agoraphobic avoidance 
was found to be a strong predictor of non-response to phar-
macotherapy and poor response to CBT.103,104 
Given that the staging model of PD is specific for panic dis-
order,86 it is also a specific marker for PD and its use is easily 
practically and economically viable in clinics. 
DISCUSSION
According to the clinimetric principles,68,87,88 a valid marker 
must be sensitive, specific, and predictive.2 Staging86 has such 
properties while biomarkers for PD present low specificity and 
low predictive value.9,10,45,49 Biomarkers would be more specif-
ic if related to specific stages of panic disorder. We here pres-
ent an attempt to enrich the staging model of panic disorder 
with stage-specific biological markers (Figure 1). Changes in 
amygdala volume, lower HRV, HPA-axis dysregulation were 
observed in generalized anxiety, social anxiety, and agora-
phobia,9-11,20,28,32 thus they may be specific for stage 1 and 2. All 
biomarkers here described were studied in samples of patients 
satisfying the DSM diagnosis of PD, thus having panic attacks. 
This suggests that these biomarkers can be specific for stage 
3 or 4. HPA-axis dysregulation, aberrant respiratory pattern, 
and changes in amygdala volume might be involved in stage 4 
given that: 1) hyperventilation might be chronic;16,17 2) high-
er cortisol levels predict higher symptoms severity at 2–4 year 
follow-up; 3) lower amygdala volumes were found in patients 
with mean (±SD) duration of illness of 5.4 (±6.4) years.11 How-
ever, this proposal has the limitation that each biomarker is 
apparently specific for more than one stage. This underlines 
the limitations already illustrated for biomarkers which, tak-
en without a clinical marker, are still aspecific and, as a con-
sequence, with limited clinical utility.
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